Compare Quest Diagnostics Inc (DGX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Southern Copper Corp — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Southern Copper Corp trades at $193.92 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 6.3× Quest Diagnostics Inc's market cap, and Southern Copper Corp pays the higher dividend (2.26%). Which is the better fit depends on your goals.
| DGX | SCCO | |
|---|---|---|
Market Cap | $26.21B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $238.50 | $218.85 |
52-Week Low | $173.49 | $93.70 |
Enterprise Value | $31.97B | $165.50B |
Dividend Yield | 1.45% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Southern Copper (SCCO) trades at $194.86, down 2.62% on the day, with a bullish technical signal from moving averages and strong support at $191. The company reported record Q2 2026 earnings, beating estimates with EPS of $1.99, driven by high metal prices, though production volumes declined. Revenue and net income have grown consistently, with 2025 revenue at $13.42B and net income at $4.33B, reflecting a net margin of 35.87%.
Outlook remains positive due to robust profitability and AI-driven copper demand, but risks include premium valuation (P/E 29.18), reliance on metal prices, and mixed analyst sentiment with a consensus price target of $153.64 below current levels. Institutional buying and strong cash flow trends support growth, yet investors face volatility from commodity cycles and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
